

Cell Therapy Biomanufacturing: Global Markets

Market Research Report | 2024-08-01 | 112 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report discusses the key trends shaping the global cell therapy biomanufacturing market, exploring factors that drive or hinder growth while providing valuable insights for stakeholders and potential newcomers. It examines R&D investment, heightened competition, and emerging technologies steering market dynamics. Moreover, the report assesses how advancements, product launches, and governmental initiatives impact future market trajectories. It also scrutinizes corporate actions like mergers, acquisitions, and partnerships. Additionally, the report evaluates the efficacy of various strategies in light of evolving technologies, intensifying competition, and shifting consumer demands.

Report Includes:

- 17 data tables and 25 additional tables
- Analysis of the global markets for cell therapy biomanufacturing
- Analyses of global market trends, with market revenue data from 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
- Estimates of the current market size and revenue prospects, along with a market share analysis by product type, application, end user and region
- Facts and figures pertaining to the market dynamics, technological advances, product launches, regulatory scenarios, and the expected impact of macroeconomic factors
- An analysis of patents and emerging technologies
- Overview of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

- An analysis of the industry structure, including companies' market shares, merger and acquisition activity, and venture funding
- Profiles of the leading companies, including Thermo Fisher Scientific Inc., Bristol-Myers Squibb Co., Lonza, Merck KGaA, and BioSeric SA

Executive Summary

Summary:

The cell therapy biomanufacturing global market was worth \$8.6 billion in 2023. The market is anticipated to achieve a CAGR of 11.5%, resulting in a value of \$16.7 billion by the end of 2029. The growth trajectory of the cell therapy biomanufacturing market is underpinned by a convergence of factors that collectively fuel its expansion and innovation. Foremost among these drivers is the escalating prevalence of chronic and degenerative diseases worldwide, accentuating the urgent need for novel therapeutic interventions. This demand is met by the remarkable strides in cell therapy technologies, marked by breakthroughs in cell engineering, gene editing, and manufacturing processes.

These advancements empower researchers and clinicians to effectively harness cells' regenerative and immunomodulatory properties, offering targeted and personalized treatment modalities for a spectrum of ailments.

Regulatory entities like the FDA and European Medicines Agency (EMA) have championed initiatives to streamline approval processes, catalyzing the development and commercialization of cell-based therapies. Initiatives like the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and the EMA's Priority Medicines (PRIME) scheme expedite the translation of promising therapies from bench to bedside, fostering a conducive regulatory environment that incentivizes investment and innovation. Indeed, robust investment and funding streams from diverse sources, including venture capital, pharmaceutical conglomerates, and governmental agencies, underscore the burgeoning interest and confidence in the market's potential. This financial backing fuels research, development, and clinical trials, propelling the proliferation of novel cell therapy solutions.

The expanding applications of cell therapy across oncology, regenerative medicine, and immune disorders widen the market's scope, offering multifaceted avenues for growth and therapeutic advancement. Breakthroughs in induced pluripotent stem cell (iPSC) therapy, mesenchymal stem cell (MSC) therapy, and chimeric antigen receptor (CAR) T-cell therapy underscore the versatility and efficacy of cell-based treatments in addressing an array of medical needs. As the industry evolves, collaborative efforts and strategic partnerships between biopharmaceutical companies, academic institutions, research organizations, and contract manufacturing organizations (CMOs) are pivotal in accelerating innovation, knowledge exchange, and technology transfer. By pooling resources, expertise, and infrastructure, stakeholders harness synergies to navigate regulatory complexities, optimize manufacturing processes, and expedite commercialization timelines. In sum, the cell therapy biomanufacturing market is poised for robust expansion. It is propelled by a confluence of factors that collectively shape its growth trajectory, spur innovation, and pave the way for transformative therapies that promise to improve patient outcomes and revolutionize healthcare standards.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

Cell Therapy

Stem Cell Transplantation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Stem Cell Biomanufacturing
Stem Cell Classification Based on Source
Stem Cell Classification Based on Ability to Differentiate
Uses of Stem Cells
Application of Stem Cells
Mechanism of Cell Therapy
Delivery Method of Cell-Based Therapy
Chapter 3 Market Dynamics
Overview
Market Drivers
Rising Prevalence of Chronic and Degenerative Diseases
Growing Investment in R&D
Technological Advancements in Bioprocessing
Expansion of Cell Therapy Manufacturing Infrastructure
Market Restraints
Complexity and Cost of Manufacturing
Supply Chain Issues
Product Stability and Shelf Life
Market Opportunities
Emerging Therapeutic Applications
Patient-Centric Healthcare Models
Chapter 4 Regulatory Structure
Regulatory Authorities
Regulatory Pathways
Quality Assurance
Manufacturing Standards
Global Harmonization Efforts
Chapter 5 Emerging Technologies and Developments
Newest Technologies/Key Developments
Advanced Cell Culture Systems
Genome Editing Technologies
Bioprocessing Innovation
Cell Sorting and Purification
Automation and Robotics
Data Analytics and Machine Learning
Tissue Engineering and Organoid Technologies
Point-of-Care Manufacturing
Chapter 6 Market Segmentation Analysis
Key Market Trends
Cell Therapy Biomanufacturing: Global Markets
Segmentation Breakdown
Market Analysis, by Product Type
Type of Therapy
Source of Cells
Market Analysis, by Application
Skeletal Muscle Repair
Bone Repair

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cancer
Cardiovascular Diseases
Neurological Disorders
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Global Company Ranking
Strategic Analysis
M&A and Venture Funding
Chapter 8 Sustainability in Cell Therapy Biomanufacturing: An ESG Perspective
Environmental Impact
Supply Chain Sustainability
Social Responsibility
Corporate Governance
Product Lifecycle Management
Energy and Water
Recycling
Process Design and Materials
Recycling Single-Use Plastics
Work Environment
Chapter 9 Appendix
Methodology
Sources
Acronyms
Company Profiles
BIOSENIC
BRISTOL-MYERS SQUIBB CO.
DANAHER CORP.
IOVANCE BIOTHERAPEUTICS INC.
LISATA THERAPEUTICS
LONZA
MERCK KGAA
THERMO FISHER SCIENTIFIC INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell Therapy Biomanufacturing: Global Markets

Market Research Report | 2024-08-01 | 112 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com